Small Cell Lung Cancer (SCLC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Small Cell Lung Cancer (SCLC) Emerging Therapy and TPP Insights

Thelansis's "Small Cell Lung Cancer (SCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Small Cell Lung Cancer (SCLC) Overview

Small cell lung cancer (SCLC) is an aggressive, high-grade neuroendocrine carcinoma of the lung characterised by rapid doubling time, early metastatic dissemination, and initial chemosensitivity invariably followed by acquired resistance and relapse, with tobacco smoking as the overwhelmingly dominant aetiological driver. Genomic hallmarks include near-universal biallelic inactivation of TP53 and RB1, alongside amplification of MYC family oncogenes, producing a highly proliferative tumour with limited targetable driver mutations and profound immunosuppressive microenvironment. Disease is staged as limited, confined to one hemithorax within a tolerable radiotherapy field, or extensive, representing the majority at diagnosis. Patients present with rapidly progressive cough, dyspnoea, haemoptysis, superior vena cava syndrome, and paraneoplastic syndromes including SIADH, Lambert-Eaton myasthenic syndrome, and encephalitis. Diagnosis integrates CT and PET staging, tissue biopsy confirming neuroendocrine morphology, and paraneoplastic antibody assessment. Atezolizumab or durvalumab combined with platinum-etoposide chemotherapy constitutes the established frontline standard for extensive-stage SCLC, delivering modest but meaningful survival improvement over chemotherapy alone. Concurrent chemoradiation with prophylactic cranial irradiation or MRI surveillance addresses limited-stage disease. Lurbinectedin is approved for platinum-refractory relapsed disease, while topotecan retains utility in selected patients. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, represents a landmark therapeutic advance demonstrating durable responses in heavily pretreated relapsed SCLC, establishing a transformative new treatment option. Prognosis remains poor with five-year survival below 7%; multidisciplinary management, early palliative integration, and patient-centred supportive care are indispensable to optimising quality of life and survival outcomes.

Key Highlights

• In Germany, survival-adjusted prevalent SCLC cases are projected to increase from 70,231 in 2025 to 75,111 by 2035.
• SCLC remains an aggressive lung cancer subtype with poor long-term survival outcomes.
• Immunotherapy integration into first-line treatment has modestly improved disease management.
• High relapse rates and rapid disease progression continue to represent major unmet needs.

Market Overview

• The Spain SCLC market is projected to grow from USD 170 million in 2025 to USD 430 million by 2035.
• Market growth is driven by adoption of immunotherapies and emerging targeted approaches.
• Future opportunities will depend on therapies improving survival and reducing relapse burden.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• AbbVie
• Daiichi Sankyo
• Puma Biotechnology, Inc.
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Zai Lab (Shanghai) Co., Ltd.
• Shanghai JMT-Bio Inc.
• Sichuan Baili Pharmaceutical Co., Ltd.
• BioNTech SE
• Akeso
• Amgen
• Merck Sharp & Dohme LLC
• Hoffmann-La Roche